261 related articles for article (PubMed ID: 23922646)
1. Peripheral reduction of FGFR4 with antisense oligonucleotides increases metabolic rate and lowers adiposity in diet-induced obese mice.
Yu XX; Watts LM; Manchem VP; Chakravarty K; Monia BP; McCaleb ML; Bhanot S
PLoS One; 2013; 8(7):e66923. PubMed ID: 23922646
[TBL] [Abstract][Full Text] [Related]
2. Role of adiponectin in the metabolic effects of cannabinoid type 1 receptor blockade in mice with diet-induced obesity.
Tam J; Godlewski G; Earley BJ; Zhou L; Jourdan T; Szanda G; Cinar R; Kunos G
Am J Physiol Endocrinol Metab; 2014 Feb; 306(4):E457-68. PubMed ID: 24381003
[TBL] [Abstract][Full Text] [Related]
3. Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice.
Yu XX; Murray SF; Pandey SK; Booten SL; Bao D; Song XZ; Kelly S; Chen S; McKay R; Monia BP; Bhanot S
Hepatology; 2005 Aug; 42(2):362-71. PubMed ID: 16001399
[TBL] [Abstract][Full Text] [Related]
4. Reduction of JNK1 expression with antisense oligonucleotide improves adiposity in obese mice.
Yu XX; Murray SF; Watts L; Booten SL; Tokorcheck J; Monia BP; Bhanot S
Am J Physiol Endocrinol Metab; 2008 Aug; 295(2):E436-45. PubMed ID: 18523126
[TBL] [Abstract][Full Text] [Related]
5. The central cannabinoid CB1 receptor is required for diet-induced obesity and rimonabant's antiobesity effects in mice.
Pang Z; Wu NN; Zhao W; Chain DC; Schaffer E; Zhang X; Yamdagni P; Palejwala VA; Fan C; Favara SG; Dressler HM; Economides KD; Weinstock D; Cavallo JS; Naimi S; Galzin AM; Guillot E; Pruniaux MP; Tocci MJ; Polites HG
Obesity (Silver Spring); 2011 Oct; 19(10):1923-34. PubMed ID: 21799481
[TBL] [Abstract][Full Text] [Related]
6. Inhibiting monoacylglycerol acyltransferase 1 ameliorates hepatic metabolic abnormalities but not inflammation and injury in mice.
Soufi N; Hall AM; Chen Z; Yoshino J; Collier SL; Mathews JC; Brunt EM; Albert CJ; Graham MJ; Ford DA; Finck BN
J Biol Chem; 2014 Oct; 289(43):30177-88. PubMed ID: 25213859
[TBL] [Abstract][Full Text] [Related]
7. FGFR4 prevents hyperlipidemia and insulin resistance but underlies high-fat diet induced fatty liver.
Huang X; Yang C; Luo Y; Jin C; Wang F; McKeehan WL
Diabetes; 2007 Oct; 56(10):2501-10. PubMed ID: 17664243
[TBL] [Abstract][Full Text] [Related]
8. Beneficial metabolic effects of CB1R anti-sense oligonucleotide treatment in diet-induced obese AKR/J mice.
Tang Y; Ho G; Li Y; Hall MA; Hills RL; Black SC; Liang Y; Demarest KT
PLoS One; 2012; 7(8):e42134. PubMed ID: 22870290
[TBL] [Abstract][Full Text] [Related]
9. Cannabinoid receptor 1 antagonist treatment induces glucagon release and shows an additive therapeutic effect with GLP-1 agonist in diet-induced obese mice.
Patel KN; Joharapurkar AA; Patel V; Kshirsagar SG; Bahekar R; Srivastava BK; Jain MR
Can J Physiol Pharmacol; 2014 Dec; 92(12):975-83. PubMed ID: 25361428
[TBL] [Abstract][Full Text] [Related]
10. The Gly385(388)Arg Polymorphism of the FGFR4 Receptor Regulates Hepatic Lipogenesis Under Healthy Diet.
Lutz SZ; Hennige AM; Peter A; Kovarova M; Totsikas C; Machann J; Kröber SM; Sperl B; Schleicher E; Schick F; Heni M; Ullrich A; Häring HU; Stefan N
J Clin Endocrinol Metab; 2019 Jun; 104(6):2041-2053. PubMed ID: 30541128
[TBL] [Abstract][Full Text] [Related]
11. CB1 antagonism exerts specific molecular effects on visceral and subcutaneous fat and reverses liver steatosis in diet-induced obese mice.
Jourdan T; Djaouti L; Demizieux L; Gresti J; Vergès B; Degrace P
Diabetes; 2010 Apr; 59(4):926-34. PubMed ID: 20110567
[TBL] [Abstract][Full Text] [Related]
12. Reduced adiposity and improved insulin sensitivity in obese mice with antisense suppression of 4E-BP2 expression.
Yu XX; Pandey SK; Booten SL; Murray SF; Monia BP; Bhanot S
Am J Physiol Endocrinol Metab; 2008 Mar; 294(3):E530-9. PubMed ID: 18198353
[TBL] [Abstract][Full Text] [Related]
13. Garcinia Cambogia attenuates diet-induced adiposity but exacerbates hepatic collagen accumulation and inflammation.
Kim YJ; Choi MS; Park YB; Kim SR; Lee MK; Jung UJ
World J Gastroenterol; 2013 Aug; 19(29):4689-701. PubMed ID: 23922466
[TBL] [Abstract][Full Text] [Related]
14. Effect of the cannabinoid receptor-1 antagonist rimonabant on inflammation in mice with diet-induced obesity.
Wang Q; Perrard XD; Perrard JL; Mansoori A; Smith CW; Ballantyne CM; Wu H
Obesity (Silver Spring); 2011 Mar; 19(3):505-13. PubMed ID: 20885384
[TBL] [Abstract][Full Text] [Related]
15. [Pharmacological therapy of obesity].
Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
[TBL] [Abstract][Full Text] [Related]
16. Peripherally acting CB1-receptor antagonist: the relative importance of central and peripheral CB1 receptors in adiposity control.
Son MH; Kim HD; Chae YN; Kim MK; Shin CY; Ahn GJ; Choi SH; Yang EK; Park KJ; Chae HW; Moon HS; Kim SH; Shin YG; Yoon SH
Int J Obes (Lond); 2010 Mar; 34(3):547-56. PubMed ID: 20029379
[TBL] [Abstract][Full Text] [Related]
17. Targeted Delivery of Stk25 Antisense Oligonucleotides to Hepatocytes Protects Mice Against Nonalcoholic Fatty Liver Disease.
Cansby E; Nuñez-Durán E; Magnusson E; Amrutkar M; Booten SL; Kulkarni NM; Svensson LT; Borén J; Marschall HU; Aghajan M; Mahlapuu M
Cell Mol Gastroenterol Hepatol; 2019; 7(3):597-618. PubMed ID: 30576769
[TBL] [Abstract][Full Text] [Related]
18. Fibroblast growth factor receptor 4 (FGFR4) deficiency improves insulin resistance and glucose metabolism under diet-induced obesity conditions.
Ge H; Zhang J; Gong Y; Gupte J; Ye J; Weiszmann J; Samayoa K; Coberly S; Gardner J; Wang H; Corbin T; Chui D; Baribault H; Li Y
J Biol Chem; 2014 Oct; 289(44):30470-30480. PubMed ID: 25204652
[TBL] [Abstract][Full Text] [Related]
19. NESS038C6, a novel selective CB1 antagonist agent with anti-obesity activity and improved molecular profile.
Mastinu A; Pira M; Pani L; Pinna GA; Lazzari P
Behav Brain Res; 2012 Oct; 234(2):192-204. PubMed ID: 22771813
[TBL] [Abstract][Full Text] [Related]
20. CB(1) antagonism restores hepatic insulin sensitivity without normalization of adiposity in diet-induced obese dogs.
Kim SP; Woolcott OO; Hsu IR; Stefanoski D; Harrison LN; Zheng D; Lottati M; Kolka C; Catalano KJ; Chiu JD; Kabir M; Ionut V; Bergman RN; Richey JM
Am J Physiol Endocrinol Metab; 2012 May; 302(10):E1261-8. PubMed ID: 22374758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
